Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1998 1
1999 1
2001 5
2002 9
2003 9
2004 8
2005 12
2006 7
2007 7
2008 6
2009 1
2010 6
2011 2
2012 5
2013 7
2014 3
2015 3
2016 4
2017 3
2018 1
2019 2
2020 1
2021 6
2022 3
2023 3
2024 4
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.
VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z. VanderPluym JH, et al. JAMA. 2021 Jun 15;325(23):2357-2369. doi: 10.1001/jama.2021.7939. JAMA. 2021. PMID: 34128998 Free PMC article.
IMPORTANCE: Migraine is common and can be associated with significant morbidity, and several treatment options exist for acute therapy. OBJECTIVE: To evaluate the benefits and harms associated with acute treatments for episodic migraine in adults. DATA …
IMPORTANCE: Migraine is common and can be associated with significant morbidity, and several treatment options exist for acute …
Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
Karlsson WK, Ostinelli EG, Zhuang ZA, Kokoti L, Christensen RH, Al-Khazali HM, Deligianni CI, Tomlinson A, Ashina H, Ruiz de la Torre E, Diener HC, Cipriani A, Ashina M. Karlsson WK, et al. BMJ. 2024 Sep 18;386:e080107. doi: 10.1136/bmj-2024-080107. BMJ. 2024. PMID: 39293828 Free PMC article.
OBJECTIVE: To compare all licensed drug interventions as oral monotherapy for the acute treatment of migraine episodes in adults. DESIGN: Systematic review and network meta-analysis. ...Certainty of the evidence was graded using the confidence in netwo …
OBJECTIVE: To compare all licensed drug interventions as oral monotherapy for the acute treatment of migraine episodes in adul …
Acute and preventive treatment of menstrual migraine: a meta-analysis.
Khoo CC, Liu CC, Lu M, Huang YC, Weng HY. Khoo CC, et al. J Headache Pain. 2024 Sep 4;25(1):143. doi: 10.1186/s10194-024-01848-6. J Headache Pain. 2024. PMID: 39227797 Free PMC article.
BACKGROUND AND OBJECTIVES: About a quarter of migraine cases among women have menstrual migraine (MM), which is usually more severe, longer lasting, and less responsive to treatment than typical migraine. Randomized controlled trials (RCTs) have evaluated the …
BACKGROUND AND OBJECTIVES: About a quarter of migraine cases among women have menstrual migraine (MM), which is usually more s …
Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G. Cameron C, et al. Headache. 2015 Jul-Aug;55 Suppl 4:221-35. doi: 10.1111/head.12601. Epub 2015 Jul 14. Headache. 2015. PMID: 26178694
BACKGROUND: Although triptans are widely used in the acute management of migraine, there is uncertainty around the comparative efficacy of triptans among each other and vs non-triptan migraine treatments. We conducted systematic reviews a …
BACKGROUND: Although triptans are widely used in the acute management of migraine, there is uncertainty around the comp …
Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC, Tang KT, Wang SJ. Yang CP, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2128544. doi: 10.1001/jamanetworkopen.2021.28544. JAMA Netw Open. 2021. PMID: 34633423 Free PMC article.
IMPORTANCE: New therapeutic classes of migraine-specific treatment have been developed, including 5-hydroxytryptamine1F receptor agonists (lasmiditan) and calcitonin gene-related peptide antagonists (rimegepant and ubrogepant). OBJECTIVE: To compare outcomes …
IMPORTANCE: New therapeutic classes of migraine-specific treatment have been developed, including 5-hydroxytryptamine1F receptor …
Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis.
Laohapiboolrattana W, Jansem P, Anukoolwittaya P, Roongpiboonsopit D, Hiransuthikul A, Pongpitakmetha T, Thanprasertsuk S, Rattanawong W. Laohapiboolrattana W, et al. J Headache Pain. 2024 Nov 8;25(1):194. doi: 10.1186/s10194-024-01904-1. J Headache Pain. 2024. PMID: 39516789 Free PMC article.
Our study aims to synthesize evidence through a systematic review and network meta-analysis to assess the comparative efficacy of lasmiditan, rimegepant and ubrogepant in triptan-insufficient responders. ...CONCLUSION: Lasmiditan, rimegepant, and ubrogepant a …
Our study aims to synthesize evidence through a systematic review and network meta-analysis to assess the comparative efficacy …
Pharmacologic Treatment of Acute Attacks of Episodic Migraine: A Systematic Review and Network Meta-analysis for the American College of Physicians.
Gartlehner G, Dobrescu A, Wagner G, Chapman A, Persad E, Nowak C, Klerings I, Neubauer C, Feyertag J, Gadinger A, Thaler K. Gartlehner G, et al. Ann Intern Med. 2025 Apr;178(4):507-524. doi: 10.7326/ANNALS-24-02034. Epub 2025 Mar 18. Ann Intern Med. 2025. PMID: 40096693
BACKGROUND: Migraine is common, affecting 15% of Americans. PURPOSE: To compare benefits and harms of pharmacologic treatments for acute attacks of episodic migraine in adults and assess cost-effectiveness. ...Triptan regimens, however, often had a hig …
BACKGROUND: Migraine is common, affecting 15% of Americans. PURPOSE: To compare benefits and harms of pharmacologic treatments for …
Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians.
Qaseem A, Tice JA, Etxeandia-Ikobaltzeta I, Wilt TJ, Harrod CS, Cooney TG, Crandall CJ; Clinical Guidelines Committee of the American College of Physicians; Hicks LA, Balk E, Cross JT Jr, Fitterman N, Lewis J, Linsky AM, Maroto M, Miller MC, Obley AJ, Owens DK, Shekelle PG, Shamliyan T, Yost J. Qaseem A, et al. Ann Intern Med. 2025 Apr;178(4):571-578. doi: 10.7326/ANNALS-24-03095. Epub 2025 Mar 18. Ann Intern Med. 2025. PMID: 40096690 Free article.
METHODS: This guideline is based on a systematic review and network meta-analysis of the comparative benefits and harms of pharmacologic treatments of acute episodic migraine headaches, as well as systematic reviews of patients' values and preferences …
METHODS: This guideline is based on a systematic review and network meta-analysis of the comparative benefits and harms of pha …
Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis.
Li G, Duan S, Zhu T, Ren Z, Xia H, Wang Z, Liu L, Liu Z. Li G, et al. J Headache Pain. 2023 Sep 18;24(1):129. doi: 10.1186/s10194-023-01662-6. J Headache Pain. 2023. PMID: 37723470 Free PMC article.
BACKGROUND: Intranasal agents may be ideal for the treatment of migraine patients. Many new acute intranasal-specific therapies have been developed, but few of them have been directly compared. The aim of this network meta-analysis (NMA) was to compare …
BACKGROUND: Intranasal agents may be ideal for the treatment of migraine patients. Many new acute intranasal-specific therapie …
Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis.
Maiti R, Mishra A, Puliappadamb HM, Jena M, Srinivasan A. Maiti R, et al. J Clin Pharmacol. 2021 Dec;61(12):1534-1544. doi: 10.1002/jcph.1962. Epub 2021 Nov 12. J Clin Pharmacol. 2021. PMID: 34472095 Review.
Monotherapy with triptans in acute migraine is ineffective in many patients and contraindicated in certain cardiovascular diseases where alternative therapeutic options are necessary to explore. This meta-analysis has evaluated the efficacy and …
Monotherapy with triptans in acute migraine is ineffective in many patients and contraindicated in certain cardiovascul …
117 results